Satellos Bioscience Announces Q1 2024 Financial Results and Operational Highlights

– Conducted preclinical toxicology studies and GMP manufacturing of SAT-3247 – On track to initiate Phase 1 first-in-human clinical trials mid-2024 – Cash balance of $33.2 million at March 31, 2024 – Invited to present at PPMD 30th annual conference to be held June 26-29, 2024 TORONTO–(BUSINESS WIRE)–Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) (“Satellos” … [Read more…]

Innate Pharma Reports First Quarter 2024 Business Update and Financial Results

First preclinical data set for IPH45, a pre-IND anti-Nectin-4 Antibody Drug Conjugate, presented as an oral presentation at AACR 2024 Progression of Sanofi-developed NK Cell Engager SAR443579/IPH6101 to Phase 2 in blood cancers Five ASCO Annual Meeting 2024 abstracts: Final TELLOMAK Phase 2 data for lacutamab in Mycosis Fungoides Two posters on IPH6501, Innate’s second … [Read more…]

ANESSA Launching “ANESSA Sunshine Project” in 12 Asian countries/regions to support children’s holistic well-being

TOKYO–(BUSINESS WIRE)–ANESSA, the No. 1 suncare brand in Asia*1 from Shiseido, is proud to unveil the ANESSA Sunshine Project, a groundbreaking initiative to promote children’s holistic well-being by safely harnessing the power of the sun. The project will begin in Japan and eventually encompass 12 Asian countries/regions where ANESSA products are sold, namely, China, Hong … [Read more…]

PACS Group, Inc. Reports First Quarter 2024 Results

Conference Call and Webcast scheduled for tomorrow, May 14, 2024, at 4:00 pm ET. FARMINGTON, Utah–(BUSINESS WIRE)–PACS Group, Inc. (NYSE: PACS) (“PACS” or the “Company”), which together with its subsidiaries is one of the largest post-acute healthcare companies in the United States, announced operating results for the first quarter of 2024, reporting net income of … [Read more…]

Harrow Announces First Quarter 2024 Financial Results

First Quarter 2024 and Recent Selected Highlights: Revenues of $34.6 million, a 33% increase over the $26.1 million realized in the prior-year quarter. Received confirmation from the Centers for Medicare & Medicaid Services (CMS) on March 20 that IHEEZO is separately reimbursable for unilateral and bilateral in-office procedures, retroactive to January 1, 2024. Recently signed … [Read more…]

Lincoln Financial Meets Shifting Customer Need for Growth and Flexibility With Revamped MoneyGuard® Product

With the launch of its newest MoneyGuard solution, Lincoln Financial continues to demonstrate its commitment to the hybrid long-term care space. RADNOR, Pa.–(BUSINESS WIRE)–Lincoln Financial Group (NYSE: LNC) is meeting shifting customer preferences for growth over guarantees1 with the launch of Lincoln MoneyGuard Market Advantage® (2024), issued by The Lincoln National Life Insurance Company, Fort … [Read more…]

Optiscan Signs Know-How Agreement with Mayo Clinic

Highlights Optiscan signs Know-How agreement with US-based Mayo Clinic to develop new endomicroscopic imaging system The companies will work together to co-develop technology for use in robotic surgery Co-development and clinical testing will commence with initial focus on robotic-assisted breast cancer surgery Mayo Clinic will take a financial interest in Optiscan’s technology MELBOURNE, Australia–(BUSINESS WIRE)–Optiscan … [Read more…]

Boundless Bio Reports First Quarter 2024 Financial Results and Corporate Highlights

BBI-355 Phase 1/2 POTENTIATE clinical trial ongoing; initiated targeted therapy combinations in patients with tumors with EGFR or FGFR oncogene amplifications First patient dosed in Phase 1/2 STARMAP clinical trial of BBI-825 in patients with tumors with resistance gene amplifications Completed $100 million IPO; pro forma cash position of approximately $200 million supports both BBI-355 … [Read more…]

Avata Biosciences Emerges to Develop Solid Dose Cannabinoid Medicines for Epilepsy and Other Neurological Diseases

Lead Candidate SAP-021 to be Developed on 505(b)(2) FDA Regulatory Pathway Based on Phase 1 Results Demonstrating Bioavailability in Comparison to Epidiolex® Patent Protected Production Technology Allows for Scalable Manufacturing of Orally Administered Capsules to Address Large Patient Populations Led by Highly Relevant Leadership Team with Deep Understanding of Cannabinoid Pharmaceutical Drug Development LONDON & … [Read more…]

Zai Lab Announces Approval of AUGTYRO™ (repotrectinib) for Patients with ROS1-positive NSCLC by China’s NMPA

The approval is based on the pivotal TRIDENT-1 trial, in which AUGTYRO achieved a high response rate and durable responses, including robust intracranial responses SHANGHAI & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that the National Medical Products Administration (NMPA) in China has approved the New Drug Application (NDA) for AUGTYRO™ … [Read more…]